Shanghai Chest Hospital

🇨🇳China

Country: 🇨🇳China

Ownership: -

Established: 1957-01-01

Employees: -

Market Cap: -

Website: http://www.shmtppp.com/hospitals/chest

Clinical Trials

Cardiac Adverse Reactions Related to Immune Checkpoint Inhibitor in NSCLC Patients

Conditions: Adverse Reactions
Immune Checkpoint Inhibitor
Cardiac Event
Non-Small Cell Lung Cancer Patients

Interventions: Drug: renin-angiotensin system inhibitors or angiotensin-receptor-neprilysin inhibitor

First Posted Date: 2020-07-16

Last Posted Date: 2020-07-16

Lead Sponsor: Shanghai Chest Hospital

Target Recruit Count: 300

Registration Number: NCT04473703

cfDNA Methylation Assay for Clinical Evaluation of Patients With Stage IA Lung Cancer After Ablation Operation

Not Applicable

Conditions: Lung Cancer

Interventions: Other: surgery
Other: ablation

First Posted Date: 2020-06-04

Last Posted Date: 2020-06-04

Lead Sponsor: Shanghai Chest Hospital

Target Recruit Count: 90

Registration Number: NCT04413656

Locations: 🇨🇳
Shanghai Chest Hospital, Shanghai, Shanghai, China

Tislelizumab Combined With Chemotherapy With or Without Bevacizumab in TKI-Resistant EGFR-Mutated Non-squamous NSCLC

Phase 2

Recruiting

Conditions: Non Small Cell Lung Cancer

Interventions: Drug: Tislelizumab
Drug: Bevacizumab
Drug: Carboplatin
Drug: Nab paclitaxel
Drug: Pemetrexed

First Posted Date: 2020-05-28

Last Posted Date: 2021-11-22

Lead Sponsor: Shanghai Chest Hospital

Target Recruit Count: 120

Registration Number: NCT04405674

Locations: 🇨🇳
Shanghai Chest Hospital, Shanghai, Shanghai, China

Pyrotinib Plus Thalidomide in Advanced NSCLC Patients Harboring HER2 Exon 20 Insertions

Phase 2

Conditions: Non-small-cell Lung Cancer

Interventions: Drug: pyrotinib combined with thalidomide

First Posted Date: 2020-05-11

Last Posted Date: 2021-01-28

Lead Sponsor: Shanghai Chest Hospital

Target Recruit Count: 39

Registration Number: NCT04382300

Locations: 🇨🇳
Department of Oncology, Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, China

Prediction Model of CP-EBUS in the Diagnosis of Lymph Nodes

Conditions: Lymph Node Disease

First Posted Date: 2020-03-31

Last Posted Date: 2020-04-02

Lead Sponsor: Shanghai Chest Hospital

Target Recruit Count: 1300

Registration Number: NCT04328792

Locations: 🇨🇳
Shanghai Chest Hospital, Shanghai, Shanghai, China

Neoadjuvant Therapy in Resectable Non-Small Cell Lung Cancer Stages IIB-IIIB

Recruiting

Conditions: Non Small Cell Lung Cancer

Interventions: Drug: anti-PD-1 or anti-PD-L1
Drug: investigator decided
Drug: EGFR-TKI, ALK inhibitor, ROS1 inhibitor

First Posted Date: 2019-12-12

Last Posted Date: 2022-07-29

Lead Sponsor: Shanghai Chest Hospital

Target Recruit Count: 200

Registration Number: NCT04197076

Locations: 🇨🇳
Oncology Department, Shanghai Chest Hospital, Shanghai, China

Clinical Study of ctDNA and Exosome Combined Detection to Identify Benign and Malignant Pulmonary Nodules

Conditions: Pulmonary Nodules

Interventions: Diagnostic Test: ctDNA and Exosome Combined Detection

First Posted Date: 2019-12-02

Last Posted Date: 2019-12-02

Lead Sponsor: Shanghai Chest Hospital

Target Recruit Count: 400

Registration Number: NCT04182893

Locations: 🇨🇳
Shanghai Chest Hospital, Shanghai, China

NGS-based Large-panel in Targeted Drug Delivery and Immunotherapy of Lung Cancer

Conditions: Lung Neoplasms

First Posted Date: 2019-11-12

Last Posted Date: 2019-11-12

Lead Sponsor: Shanghai Chest Hospital

Target Recruit Count: 2000

Registration Number: NCT04159337

Locations: 🇨🇳
Shanghai Chest Hospital, Shanghai, Shanghai, China

Comparison of Esophagectomy and Chemoradiation for Patients With cN0-pT1b Stage Esophageal Squamous Cell Carcinoma

Phase 3

Recruiting

Conditions: Esophageal Cancer

Interventions: Procedure: esophagectomy
Combination Product: chemoradiation
Other: active surveillance

First Posted Date: 2019-10-22

Last Posted Date: 2019-10-22

Lead Sponsor: Shanghai Chest Hospital

Target Recruit Count: 176

Registration Number: NCT04135664

Locations: 🇨🇳
The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China
🇨🇳
Changhai Hospital, The Second Military Medical University, Shanghai, China
🇨🇳
Ruijin Hospital, Shanghai Jiao Tong University, School of Medicine, Shanghai, China

and more 3 locations

To Evaluate the Efficacy of Afatinib in Advanced Lung Squamous Cell Carcinoma With EGFR Sensitive Mutation

Phase 4

Conditions: Lung Squamous Cell Carcinoma

Interventions: Drug: Afatinib

First Posted Date: 2019-10-18

Last Posted Date: 2019-10-29

Lead Sponsor: Shanghai Chest Hospital

Target Recruit Count: 20

Registration Number: NCT04132102

Locations: 🇨🇳
Shanghai Chest Hospital, Shanghai, Shanghai, China

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy